Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
Holly Janes, Leigh H Fisher, Jia Jin Kee, Lalitha Parameswaran, Paul A Goepfert, Ann R Falsey, James Ludwig, Craig A Magaret, Peter B Gilbert, James G Kublin, Nadine Rouphael, Magdalena E Sobieszczyk, Hana M El Sahly, Lindsey R Baden, Beatriz Grinsztejn, Stephen R Walsh, Glenda E Gray, Karen L Kotloff, Cynthia L Gay, Alexander L Greninger, Milagritos D Tapia, E Adrianne Hammershaimb, Frances H Priddy, Justin A Green, Frank Struyf, Lisa Dunkle, Kathleen M Neuzil, Lawrence Corey, Yunda Huang
J Infect Dis 230(6) 1384-1389
摘要
摘要
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
KM 提取结果
0 个 Figure · 0 个 KM 面板